ENDPOINTS

Inspirna, which was preparing for a Phase 3 cancer trial, has folded

A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is shutting down, a blow to a company that was prepping for a pivotal ...

Mar 31, 2025 - 15:50
 0
Inspirna, which was preparing for a Phase 3 cancer trial, has folded
A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is shutting down, a blow to a company that was prepping for a pivotal ...
Read More

Tags:

Previous Article

SWERY Believes VR Will Become “The Next Major Computing Platform”

Next Article

Alphabet’s Isomorphic Labs raises $600M in biotech’s largest round of 2025 

Related Posts

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia

Lilly claims Phase 2 win for siRNA approach to mixed dy...

Apr 1, 2025  0

First meeting of CDC vaccine advisors in the Kennedy era is postponed

First meeting of CDC vaccine advisors in the Kennedy er...

Feb 20, 2025  0

Novo looks to recoup $830M from hypertension drug partner

Novo looks to recoup $830M from hypertension drug partner

Feb 18, 2025  0